Positive high-level results from an interim analysis of the AMPLIFY phase III trial showed a fixed duration of Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemoimmunotherapy in previously untreated adult patients with chronic lymphocytic leukemia.
IMUNON Inc., a clinical-stage company in late-stage development of its DNA-mediated immunotherapy, announced positive topline results from the phase II OVATION 2 study with IMNN-001 in patients with advanced ovarian cancer.Â
A study published in Nature reveals the functional relevance of tumor-neuron interactions that regulate the growth of ependymoma brain tumors.Â
OncoHost, a technology company, announced the publication of a study in Clinical Lung Cancer demonstrating the impact of its PROphetNSCLC test on first-line treatment decisions for metastatic non-small cell lung cancer patients.
AI system identifies genes that can convert brain cancer cells into functioning immune cells in mice
In an innovative new study of glioblastoma, scientists used artificial intelligence to reprogram cancer cells, converting them into dendritic cells, which can identify cancer cells and direct other immune cells to kill them.
Tumors with alterations in any of three specific genes were more likely than other tumors to be eliminated by cisplatin-based chemotherapy.
Researchers at UT Southwestern Medical Center have discovered that a diet free of the amino acid tryptophan can effectively halt the growth of liver cancer in mice. Their findings, published in Nature Communications, offer new insights for dietary-based cancer treatments and highlight the critical role of the tryptophan metabolite indole 3-pyruvate (I3P) in liver tumor development.
Targeting a protein called ZFP574 suppressed leukemia in a mouse model of the disease, UT Southwestern Medical Center researchers showed in a new study. Their findings, published in PNAS, could lead to new treatments for leukemias and lymphomas in cancer patients.
Bintrafusp alfa, a novel bispecific antibody, achieved an objective response rate of 22% in women with recurrent or metastatic cervical cancer in a phase II nonrandomized controlled trial.Â
Socioeconomic factors can influence the diagnosis and treatment of children in Texas with malignant solid tumors, increasing the risk of the cancer’s spread and lowering the five-year survival rate, according to researchers at UT Southwestern Medical Center.Â
